TrialLineage Concept
Retinal biology
The retina is a thin layer of tissue at the back of the eye that converts light into electrical signals sent to the brain. Understanding its cellular architecture — photoreceptors, retinal pigment epithelium, and supporting layers — is foundational to explaining why inherited retinal diseases cause vision loss and how gene therapy can intervene.
In plain language
How the retina works
The retina contains two main types of light-sensing cells: rods (which detect dim light and enable night vision) and cones (which detect color and enable sharp central vision). These photoreceptors depend on the retinal pigment epithelium (RPE), a supporting layer that recycles visual pigment, removes waste, and maintains photoreceptor health.
When genes essential to photoreceptor or RPE function are mutated, cells degenerate progressively. Because the retina does not regenerate in humans, lost cells are not replaced — making timing of intervention critical.
Why retinal biology matters for gene therapy
The retina’s properties made it an early candidate for gene therapy: it is small (requiring low vector doses), surgically accessible, relatively immune-privileged (reducing rejection risk), and directly measurable (through vision tests and imaging). These features reduced the technical barriers that slowed gene therapy in other organs.
Understanding which cell types express which genes also determines where vectors must deliver their cargo. RPE65, for example, is expressed in RPE cells — so the vector must reach that specific layer.
Position in the scientific lineage
Retinal biology is the foundational layer that explains why specific mutations cause specific patterns of vision loss, why certain cells are targetable, and why the timing window for intervention matters. Without detailed knowledge of retinal architecture, gene therapy design would have no target map.
Related concepts